The healthcare industry is experiencing a profound shift. Artificial intelligence, global cooperation, and new production models are reshaping how treatments are discovered, delivered, and regulated. These changes bring forward important questions: how can innovation remain ethical, accessible, and human-centered? And who is helping connect these dimensions in practice?
Artificial intelligence has become one of the most influential forces in modern medicine. It accelerates diagnostics, supports vaccine development, and processes vast volumes of medical data. AI can detect patterns that humans would miss and assist in creating more personalized therapies.
But as technology evolves, so do its challenges. Ethical concerns, algorithmic bias, and unequal access to digital innovation are now central elements of the public debate. Addressing these issues requires leaders who understand both the opportunities of AI and the responsibility that comes with applying it in critical environments.
During the workshop, Dr. Selena Milanovic highlighted how meaningful healthcare innovation emerges when technical expertise meets ethical awareness. With experience across biomedical research, industry, and public policy, she has worked on integrating AI into cardiovascular imaging and supporting evidence-based decision-making during the COVID-19 crisis.
Her background demonstrates the importance of bridging traditionally separate fields. When research, policy, and industry operate together, technology can become more inclusive, effective, and aligned with real-world needs. One example discussed was the collaborative vaccine production initiative in Rwanda, developed with Siemens AG, BioNTech, and the Gates Foundation. The project aims to reduce Africa’s reliance on imported vaccines by supporting local production, a concrete step toward democratizing healthcare.
A key theme of the session was the shift from linear to circular innovation. Instead of moving from research to industry to policy as separate phases, modern healthcare requires constant dialogue among all parties involved. This approach helps maintain balance between progress and protection, especially as new regulations, such as the EU AI Act, attempt to keep pace with fast-moving technologies.
Effective governance depends on collaboration rather than rigid control. Laws and systems must evolve alongside innovation, ensuring both safety and opportunity.
The workshop offered Rome Business School students and alumni a practical view of how cross-sector cooperation can build more resilient healthcare systems. From AI ethics to global access strategies, the discussion reinforced how multidisciplinary thinking is essential for future leaders.
This perspective aligns with the mission of Rome Business School, which prepares professionals to navigate global challenges with responsibility and vision. Through its master’s programs and executive education initiatives, including the Master in Pharma and Health Management, RBS promotes ethical awareness and strategic innovation. Students are encouraged to view technological progress not only as a business asset, but also as a societal duty.
The future of healthcare will depend on leaders who can align innovation with purpose. When ethics, technology, and collaboration move together, progress becomes a bridge rather than a barrier. Rome Business School remains committed to shaping these leaders: professionals ready to transform knowledge into global impact.
